恶性胸腔积液管理进展  

Progress of Management for Malignant Pleural Effusions

作　　者：杜小兵 刘双 DU Xiaobing;LIU Shuang(Department of Pulmonary and Critical Care Medicine,Peking University International Hospital,Beijing 102206,China)

机构地区：[1]北京大学国际医院呼吸与危重症医学科

出　　处：《中国继续医学教育》2019年第16期88-91,共4页China Continuing Medical Education

基　　金：“十二五”国家科技攻关计划(2012ZX09303016-001)

摘　　要：恶性胸腔积液是由恶性肿瘤通过直接或间接侵犯胸膜或胸膜原发性肿瘤所致。它是癌症晚期常见的并发症,治疗难度大,预后较差。患者以MPE为首发症状或恶性肿瘤进展并发胸腔积液,往往提示病情已处于晚期,生存期仅4~7个月左右。目前,恶性胸腔积液治疗的方法较多,但是没有标准的治疗方法,总体疗效有限,由于其预后不佳,临床上多以姑息治疗手段为主。因此,采取积极有效的治疗措施以缓解患者症状、提高患者生存质量,显得尤为重要。文章综合性的回顾了恶性胸腔积液的治疗方法,就晚期恶性胸腔积液的管理进行简要分析。Malignant pleural effusions(MPE)is one of the most common causes of pleural effusion.It is caused by direct or indirectly violation to the pleura or pleural primary tumor from malignant tumors.It is a common and difficult complication of advanced malignant diseases,with poor prognosis.Patients with MPE as the first symptom or malignant tumor progression complicated by pleural effusion often indicate that the disease is in the advanced stage,the survival period is only about 4~7 months.At present,there are a lot of therapies,but there is no standard treatment,the optimal treatment is controversial and the general effect is limited,because of its poor prognosis,several studies favor to local palliative approaches.Therefore,it is particularly important to take active and effective treatment measures to alleviate the symptoms of patients and improve the quality of life of patients.This article reviews the comprehensive treatment methods and current approaches to the management of malignant pleural effusion,and shows some advice to the future.

关 键 词：恶性胸腔积液 管理 进展 胸腔穿刺术 胸膜固定术 胸腔置管术 

分 类 号：R730[医药卫生—肿瘤]